Westra_1986_Br.J.Anaesth_58_1303

Reference

Title : Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients - Westra_1986_Br.J.Anaesth_58_1303
Author(s) : Westra P , van Thiel MJ , Vermeer GA , Soeterbroek AM , Scaf AH , Claessens HA
Ref : British Journal of Anaesthesia , 58 :1303 , 1986
Abstract : The pharmacokinetics of the long-acting anticholinesterase drug, galanthamine, were investigated in eight patients. After i.v. injection of 0.3 mg kg-1, the decrease in the serum concentration of galanthamine followed a biexponential curve. The serum concentration decreased rapidly from 543 +/- 47 ng ml-1 to 128 +/- 14 ng ml-1 between 2 and 30 min with a T1/2 alpha of 6.42 +/- 2.15 min, and then declined more slowly with a T1/2 beta of 264 +/- 28 min. Total serum clearance of galanthamine amounted to 5.37 +/- 0.87 ml min-1 kg-1, and the renal clearance was 1.36 +/- 0.10 ml min-1 kg-1. The cumulative urinary excretion of galanthamine between 0 and 48 h after injection amounted to 28.0 +/- 5.4% of the administered dose. The biliary excretion of galanthamine during 24 h amounted to 0.2 +/- 0.1% of the dose. There was no evidence of glucuronide or sulphate conjugation of galanthamine.
ESTHER : Westra_1986_Br.J.Anaesth_58_1303
PubMedSearch : Westra_1986_Br.J.Anaesth_58_1303
PubMedID: 3778794

Related information

Inhibitor Galanthamine

Citations formats

Westra P, van Thiel MJ, Vermeer GA, Soeterbroek AM, Scaf AH, Claessens HA (1986)
Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients
British Journal of Anaesthesia 58 :1303

Westra P, van Thiel MJ, Vermeer GA, Soeterbroek AM, Scaf AH, Claessens HA (1986)
British Journal of Anaesthesia 58 :1303

Array
(
    [id] => 49630
    [paper] => Westra_1986_Br.J.Anaesth_58_1303
    [author] => Westra P || van Thiel MJ || Vermeer GA || Soeterbroek AM || Scaf AH || Claessens HA
    [year] => 1986
    [title] => Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients
    [journal] => British Journal of Anaesthesia
    [volume] => 58
    [page] => 1303
    [medline] => 3778794
    [abstract] => Westra_1986_Br.J.Anaesth_58_1303
    [kin_reference] => 
    [mutation] => 
    [kinetic_parameter] => 
    [inhibitor] => Galanthamine
    [kin_value] => 
    [substrate] => 
    [gene_locus] => Array
        (
        )

    [family] => 
    [interact_gene_locus] => 
    [xenobiotic_sensitivity] => 
    [news] => 
    [likid_reference] => 
    [lip_reference] => 
    [gene_locus_frgt] => 
    [structure] => 
    [comment] => 
    [chemical] => 
    [arpigny_jaeger] => 
    [reactivator] => 
    [disease] => 
    [enzyme] => 
    [risk_factor] => 
    [tissue] => 
    [sub_tissue] => 
    [activity] => 
    [specific_activity] => 
    [disease_by_interaction] => 
    [abstract_text] => Array
        (
            [id] => 20011
            [longtext] => Westra_1986_Br.J.Anaesth_58_1303
            [content] => The pharmacokinetics of the long-acting anticholinesterase drug, galanthamine, were investigated in eight patients. After i.v. injection of 0.3 mg kg-1, the decrease in the serum concentration of galanthamine followed a biexponential curve. The serum concentration decreased rapidly from 543 +/- 47 ng ml-1 to 128 +/- 14 ng ml-1 between 2 and 30 min with a T1/2 alpha of 6.42 +/- 2.15 min, and then declined more slowly with a T1/2 beta of 264 +/- 28 min. Total serum clearance of galanthamine amounted to 5.37 +/- 0.87 ml min-1 kg-1, and the renal clearance was 1.36 +/- 0.10 ml min-1 kg-1. The cumulative urinary excretion of galanthamine between 0 and 48 h after injection amounted to 28.0 +/- 5.4% of the administered dose. The biliary excretion of galanthamine during 24 h amounted to 0.2 +/- 0.1% of the dose. There was no evidence of glucuronide or sulphate conjugation of galanthamine.
        )

)